Analysts Set Immunocore Holdings plc (NASDAQ:IMCR) Price Target at $58.89

Shares of Immunocore Holdings plc (NASDAQ:IMCR - Get Free Report) have been given an average rating of "Moderate Buy" by the eleven brokerages that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have given a buy rating to the company. The average twelve-month target price among analysts that have updated their coverage on the stock in the last year is $58.89.

IMCR has been the topic of a number of recent research reports. Deutsche Bank Aktiengesellschaft began coverage on shares of Immunocore in a research note on Tuesday, May 27th. They set a "buy" rating and a $65.00 price target on the stock. Mizuho decreased their price objective on Immunocore from $38.00 to $33.00 and set a "neutral" rating for the company in a report on Monday, April 7th. Morgan Stanley reiterated an "equal weight" rating and issued a $35.00 price objective on shares of Immunocore in a research report on Friday, March 7th. HC Wainwright reissued a "buy" rating and issued a $100.00 target price on shares of Immunocore in a report on Monday. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $71.00 price objective on shares of Immunocore in a research note on Thursday, April 10th.

Insider Activity

In related news, Director Bros. Advisors Lp Baker bought 807,338 shares of Immunocore stock in a transaction dated Monday, March 17th. The stock was acquired at an average cost of $29.72 per share, with a total value of $23,994,085.36. Following the completion of the acquisition, the director now directly owns 2,144,060 shares in the company, valued at approximately $63,721,463.20. This trade represents a 60.40% increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders own 10.40% of the company's stock.

Institutional Investors Weigh In On Immunocore

Hedge funds have recently modified their holdings of the stock. GF Fund Management CO. LTD. purchased a new stake in Immunocore in the 4th quarter worth about $25,000. Oppenheimer Asset Management Inc. purchased a new stake in shares of Immunocore during the 1st quarter worth about $225,000. Checkpoint Capital L.P. purchased a new stake in shares of Immunocore during the 1st quarter worth about $267,000. Banque Transatlantique SA purchased a new stake in shares of Immunocore during the 1st quarter worth about $278,000. Finally, NEOS Investment Management LLC raised its stake in shares of Immunocore by 10.9% during the 4th quarter. NEOS Investment Management LLC now owns 11,194 shares of the company's stock worth $330,000 after purchasing an additional 1,102 shares in the last quarter. 84.50% of the stock is owned by hedge funds and other institutional investors.

Immunocore Price Performance

Shares of NASDAQ:IMCR traded up $0.32 during midday trading on Wednesday, reaching $38.02. 201,968 shares of the company's stock traded hands, compared to its average volume of 373,457. Immunocore has a 1 year low of $23.15 and a 1 year high of $43.36. The company has a market cap of $1.91 billion, a P/E ratio of -40.02 and a beta of 0.83. The company has a debt-to-equity ratio of 1.03, a quick ratio of 3.76 and a current ratio of 3.78. The company has a fifty day simple moving average of $29.89 and a two-hundred day simple moving average of $30.12.

Immunocore (NASDAQ:IMCR - Get Free Report) last announced its quarterly earnings data on Wednesday, May 7th. The company reported $0.10 earnings per share for the quarter, beating analysts' consensus estimates of ($0.35) by $0.45. The company had revenue of $125.13 million for the quarter, compared to analyst estimates of $108.82 million. Immunocore had a negative return on equity of 12.84% and a negative net margin of 15.87%. The firm's revenue for the quarter was up 33.6% on a year-over-year basis. During the same quarter last year, the firm posted ($0.49) EPS. Equities analysts predict that Immunocore will post -0.94 EPS for the current fiscal year.

Immunocore Company Profile

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma.